Tumor assessment should include HER3 characterization pre and post therapy initiation, and novel imaging modalities may allow for non-invasive detection for a personalized therapeutic targeted approach as summarised in the schematic in Fig. 7. The gene discussed is ERBB3; the disease is neoplasm.